Luliconazole is a novel imidazole antibacterial candidate for treating fungal infections on the skin. Its current treatment is limited by extremely poor and sluggish skin absorption, necessitating long-term, repetitive dosing to cure the condition completely. Niosomes are becoming essential in medication delivery due to their potential to minimize toxicity and alter pharmacokinetics and bioavailability. Luliconazole niosomes were created utilizing a thin-film hydration process with varied ratios of non-ionic surfactants Span 40 and cholesterol to increase poor skin penetration and decrease adverse effects of topical traditional medication administration (CHO). The regular particle size of the Niosomal formulation was determined to be between 3 and 6.5 micrometers. The entrapment efficiency of the Niosomal formulation FN3 (1: 1) of cholesterol and Span 40 was excellent (88.56 percent). The Niosomal formulation was spherical using transmission electron microscopy (TEM). At (1: 1) cholesterol: Span 40 ratio, Niosomal formulation (FN3) showed a high proportion of drug release after 24 hours (79.87 percent).
Furthermore, a chosen Niosomal formulation was employed to create a topical gel assessed in pH, viscosity, spreadability, and ex vivo research. In an ex vivo research, Niosomal gel outperformed regular topical gel in terms of skin permeability. These results showed that Niosomal gel has a high potential for use as a new, nanosized drug delivery medium for transdermal Luliconazole delivery.
IJPRAS
